Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 10,201–10,300 of 10,906
5 factors that could dictate the success or failure of the COVID-19 vaccine rollout
Bridle, B. W. (2021) · The Conversation · doi:10.64628/aam.spkjkhnr6
Jiang, M., Akers, N. K., Gill, D. B., Eckhert, B., Svejnoha, E., & Robins, H. S. (2022) · medRxiv · doi:10.1101/2022.07.01.22277108
CEI: A Clonal Expansion Identifier for T-cell receptor clones following SARS-CoV-2 vaccination
Pan, Y., Hofmann, C., Banbury, B. L., Patel, H., Bien, S. A., Chou, T., & Yang, O. O. (2026) · Journal of Immunological Methods · doi:10.1016/j.jim.2026.114088
Nguyễn, V. H., Crépey, P., Williams, B. A., Welch, V., Pivette, J. M., Jones, C. H., & True, J. M. (2025) · Vaccines · doi:10.3390/vaccines13080828
“The high effectiveness scenario assumed an effectiveness of 92% against symptomatic disease and 97% against hospitalization, based on data from mRNA COVID-19 vaccines [8,9,12].”
Betting on Biology: Rethinking Probability as the Currency of Risk in Biotechnology Portfolios
Krishna, R. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01290-3
“The clinical and commercial success of mRNA vaccines developed, as an example, by Moderna and BioN-Tech transformed perceptions of modality risk within a short timeframe (12, 13).”
Wang, K., Zeng, T., Guo, Z., Liang, J., Sun, S., Ni, Y., Yan, C., Yin, L., Wang, L., Li, H., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10250-1
Advances in FRET-based Applications Within Biomimicking Molecular Self-assemblies
Chatterjee, A., & Purkayastha, P. (2026) · Journal of Fluorescence · doi:10.1007/s10895-026-04883-5
Solomon, O., Adams, C., Horton, M. K., Wong, M. P., Meas, M., Shao, X., Fedrigo, I., Hernandez, S., Quach, H., Quach, D. L., et al. (2022) · medRxiv · doi:10.1101/2022.09.30.22280166
Zettinig, G. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00173-0
Imagination and Idealism After the COVID-19 Pandemic
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0005
A Comparative Review of mRNA, Viral Vector, Inactivated, and Protein Subunit COVID-19 Vaccines
Payal, G., Vaishnavi, J., & Sunil, R. (2025) · International Journal of Community Pharmacy · doi:10.65301/ijcp.2025.6.2.5
Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-7688-3_5
The Story of a Pandemic Foretold
Salgues, B., & Barnouin, J. (2022) · Wiley eBooks · doi:10.1002/9781394163755.ch2
Vaccination Considerations for Adult International Travelers Living with HIV
Pandis, D., & Jairamdas, K. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105078
Outbreak of Deadly Coronavirus (COVID-19) Pandemic: Diagnosis and Management
Tiwari, A., Singh, D., Kumar, D., Chandra, V., Vishvakarma, N. K., Shukla, D., Jha, H., & Singh, R. P. (2024) · Springer eBooks · doi:10.1007/978-981-97-4723-8_15
Erratum to: Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?
Harper, J., Betts, M. R., Lichterfeld, M. D., Müller-Trutwin, M. C., Margolis, D. M., Bar, K. J., Li, J. Z., McCune, J. M., Lewin, S. R., Kulpa, D. A., et al. (2024) · Pathogens and Immunity · doi:10.20411/pai.v8i2.696
mRNA lipid nanoparticle vaccines: current status, challenges and future prospects
吴志能, Lou, J., Cheng, Y., Li, M., Wang, Z., Liu, N., Gao, X., Zheng, A., & Zhang, H. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00600-7
“DSPC contains saturated long-chain fatty acids and has a cylindrical shape, providing high physical stability and rigidity under physiological conditions; it is widely used in clinically approved mRNA vaccines, such as Moderna’s mRNA-1273 and BioNTech/Pfizer’s BNT162b2 [72].”
Three-Dose Vaccination-Induced Immune Responses Protect Against SARS-CoV-2 Omicron BA.2Preprint
Zhou, R., Liu, N., Li, X., Peng, Q., Yiu, C.-K., Huang, H., Yang, D., Du, Z., Kwok, H., Au, K., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4123263
Duverger, C., Monteil, C., Souyri, V., & Fournier, S. (2024) · American Journal of Infection Control · doi:10.1016/j.ajic.2024.01.004 · Cited by 1
Lu, X., Hayashi, H., Ishikawa, E., Takeuchi, Y., Dychiao, J. V. T., Hironori Nakagami, A., & Yamasaki, S. (2024) · eLife · doi:10.7554/elife.89999.3
Minicircle DNA Vaccines: Overcoming Delivery and Expression Barriers in Next-Generation Immunization
Alduhaymi, I. S., Majrashi, M. A., Alradwan, I. A., Alagrafi, F., Altammami, M. A., Aldossary, A. M., Almughem, F. A., Alshehri, A. A., Fallatah, M., Fayez, N. A., et al. (2026) · Vaccines · doi:10.3390/vaccines14070563
“…translation and emergency authorization of mRNA vaccines during the COVID-19 pandemic, demonstrating their suitability for widespread human use [138,139]. with mRNA-LNP systems, DNA-based platforms, including mcDNA, require nuclear entry prior to transcription, which can delay antigen expression.”
Bermúdez-Méndez, E., Lenart, K., Cerveira, R. A., Engstrand, O., Hellgren, F., Cagigi, A., Ols, S., Jasny, E., Reinhardt, A., Petsch, B., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01492-y · Cited by 1
Han, X., Wang, W., & Wang, Y. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.179648
Shao, J., Zhang, C., She, G., Qin, T., Zhang, J. C., Fang, M., Zhao, D., Wang, L., 夏丽娟, Yang, Q., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1849279
Sharma, P., Tiwari, S., Park, N., & Szeleszczuk, Ł. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177864
“LNP technology tested by Onpattro subsequently allowed the rapid production of mRNA vaccines against COVID-19 (Pfizer-BioNTech, Moderna), demonstrating how preclinical OoC nanotechnology integration accelerates broad translational impact [51].”
Bathula, N. V., Soriano, S. K. V., Huang, C., Jan, E., Sagan, S. M., & Blakney, A. K. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.004 · Cited by 1
Ciomaga, B.-F., Pascu, C., & Ionescu, G. O. (2022) · Romanian Archives of Microbiology and Immunology · doi:10.54044/rami.2022.03.02
Respiratory mucosal vaccines for emerging viruses: promise and challenges
Beeton, K., & Case, J. B. (2026) · Journal of Virology · doi:10.1128/jvi.01748-25
“A similar pattern was seen with systemically administered SARS-CoV-2 vaccines, which initially provided high levels of protection but became less effective as viral evolution gave rise to immune escape variants (24, 118).”
Taito, K., Oka, M., Sugimoto, H., Fukagawa, H., Izawa, A., Tsuchiya, T., Matsuno, S., Yamanaka, N., Yumura, W., Suzuki, N., et al. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02740-6
“The well-established efficacy of COVID-19 vaccination in preventing severe COVID-19 by 50–100% [31–33] is corroborated by the findings of the present study on the relationships among vaccination, cytokine storms, and respiratory failure.”
35915 Lipid-based nanoparticles for nucleic acids delivery
Sarnelli, S., Cardamone, M., Reverchon, E., & Baldino, L. (2025) · De Gruyter eBooks · doi:10.1515/9783111394558-015 · Cited by 3
Sung, W., Li, T., & Takeoka, S. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1888079
“Among these, mRNA-based LNP vaccines have achieved remarkable success during the COVID-19 pandemic, exemplified by those developed by Pfizer-BioNTech (Polack et al., 2020) and Moderna (Baden et al., 2021).”
Generation of efficacy data on 60 years and older population using SARS-CoV-2 vaccines
Ghosh, P. (2021) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_34_21 · Cited by 1
Past achievements and future perspectives of personalized vaccines and the role of dendritic cells
Larijani, M. S., Bavand, A., Moradi, L., & Ramezani, A. (2026) · Immunologic Research · doi:10.1007/s12026-026-09812-z
Yu, M., Wang, L., Elliott, T., Wang, X., Mathew, A., Qiu, B., Yao, L., Wang, W., & Zhang, N. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.180282 · Cited by 1
Imagination and idealism after the COVID-19 pandemic: the science of healthy ageing
Farrelly, C. (2024) · Royal Society Open Science · doi:10.1098/rsos.231102
Chimeric Antigen Cytotoxic Receptors for In-Vivo Engineering of Tumor-targeting Natural Killer CellsPreprint
Diwanji, N., Getts, D. R., & Wang, Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.07.565144
Domen, J., Abrams, S., Digregorio, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4002710/v1
Chondrocalcin: Insights into its regulation and multi-function in cartilage and bone
Zhu, W., Zhao, Z., Yuwen, W., Qu, L., Duan, Z., Zhu, C., & Fan, D. (2025) · Differentiation · doi:10.1016/j.diff.2025.100861
COVID-19 Vaccines: A Comprehensive Review of Development, Action Mechanisms, and Global Implications
Yadav, S. R., & Chougule, P. (2024) · Coronaviruses · doi:10.2174/0126667975268518240111113733
Targeted mRNA Delivery Using Bispecific Antibody-Lipid Nanoparticle Complexes
Hickey, J., Roach, T., Cassaidy, B., Hergesheimer, R., Franklin, N. M., Morin, J., Herrick-Wagman, S., Cohen, J. D., Morrissey, D., Chaparro‐Riggers, J. F., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00239
Wang, S., Zhang, X., Hu, X., Li, Y., Qiu, L., Zhang, X., Wang, W., (176511), L. W., Li, Y., Chen, Z., et al. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2026-0119
SARS-CoV-2 – ein Update zu Hautmanifestationen, prädiktiven Markern und kutanen Impfreaktionen
Drerup, K. A., & Gläser, R. (2021) · Der Hautarzt · doi:10.1007/s00105-021-04881-7
Prävention und Gesundheitsförderung
(2023) · Elsevier eBooks · doi:10.1016/b978-3-437-23571-9.00009-2
(2022) · doi:10.1101/2022.06.23.22276809 · Cited by 17
Complement is Primarily Activated in the Lung in a Severe COVID-19 Mouse ModelPreprint
Szachowicz, P. J., Wohlford-Lenane, C., Heinen, C. J., Ghimire, S., Xue, B., Boly, T. J., Verma, A., MašinoviĆ, L., Bermick, J., Perlman, S. M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4878210
Neuroimmunology and Neurological Manifestations of COVID-19
Weissert, R. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.103026
ОСОБЛИВОСТІ ФОРМУВАННЯ ІМУННОЇ ВІДПОВІДІ ПІСЛЯ ВАКЦИНАЦІЇ ВІД COVID-19
Кисельова, Г. Л., Анастасій, І. А., Тонковид, О. Б., Isaiev, V. M., Voronova, K., Шевель, І. І., Сідорова, І. В., Карпеченко, С. В., & Панченко, А. А. (2023) · Інфекційні хвороби · doi:10.11603/1681-2727.2022.4.13697
Cheng, M. T. K., Keen, J. L., Frost, S., et al. (2026) · medRxiv · doi:10.64898/2026.01.19.26344403
mRNA based vaccines as an alternative to conventional vaccine approaches
Zubda-tul, H., & Muhammad, Q. (2022) · Open Journal of Environmental Biology · doi:10.17352/ojeb.000026
Georgieva, M. V., Sun, T., & Beck, E. C. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01039-5
Kinganda-Lusamaki, E., Ortega‐Villa, A. M., Camara, D., Haidara, M. C., Blie, J., Coulibaly, N., Dewar, R. L., Kallon, K., Rehman, T., Sereti, I., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-69510-6
Self-citationInfectiologie : vaccins contre la COVID-19
Aupiais, C. (2021) · Perfectionnement en Pédiatrie · doi:10.1016/s2588-932x(21)00197-2
Sábato, S., Benet, S., Rogers, A. J., Murray, T. A., Skeans, M. A., Mothe, B., Paredes, R., Mourad, A., Kiweewa, F., Kamel, D., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-92742-x
“Consequently, there is limited information on immunogenicity of COVID-19 vaccines following SARS-CoV-2 infection, and it comes mostly from observational studies 2,3,21 .”
Gründe für allergologische Diagnostik und deren Ergebnisse im Kontext von COVID-19-Vakzinierungen
Floruß, E. L., Demidova, A., Hofmann, S. C., & Balakirski, G. (2023) · Die Dermatologie · doi:10.1007/s00105-023-05152-3
da Silva, J. R. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2021.tde-17032022-102622 · Cited by 1
Girndt, M. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00867-x
Kim, S., Park, S. H., Choi, S., Lee, W., Choi, S., Han, S., Han, S., & Lee, D. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2467554 · Cited by 2
Self-citationmRNA-1273-SARS-CoV-2-Impfstoff
(2021) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-1393-5079
Miyamoto, N., Yamaguchi, T., Tamada, Y., Yamayoshi, S., Murashita, K., Itoh, K., Imoto, S., Saito, N., Mikami, T., & Nakaji, S. (2026) · Vaccines · doi:10.3390/vaccines14020115
“In Japan, the COVID-19 vaccines Comirnaty from Pfizer Inc. [10], Spikevax from Moderna Inc. [11], and Vaxzevria from AstraZeneca PLC [12] were approved as medical drugs since 2021.”
Eritema palpebral tras vacunación frente a la infección por coronavirus
Bárcena-Dahl, A., Bonivento-Martínez, V., & de Pipaón, M. R.-P. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.06.026
Dziadzio, M. (2021) · Journal of Immunology and Allergy · doi:10.37191/mapsci-2582-6549-2(2)-024
Persano, I., Cani, M., Rio, B. D., Ferrari, G., Garbo, E., Parlagreco, E., Pisano, C., Cetoretta, V., Delcuratolo, M. D., Turco, F., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010165
Isono, T., Kojima, A., Nishida, T., Kobayashi, Y., Ishiguro, T., Takaku, Y., Kagiyama, N., & Kurashima, K. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4276-24
Seo, E. J., Jung, M. S., Lee, K., Kim, K. T., & Choi, M. Y. (2024) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2023.0090 · Cited by 1
Nakaharai, K., Nakazawa, Y., & Yoshida, M. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.08.016
Parra-Izquierdo, V., Remolina-Granados, S. A., & Romero‐Sánchez, C. (2021) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.785
Birtolo, L. I., Pietro, G. D., D’Ascenzio, F., Cuccuru, G., Fabris, E., Merlo, M., Andreis, A., Cameli, M., Improta, R., Campo, G. C., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4859906
SARS-CoV-2 Omicron (B.1.1.529) Varyantının Virolojik, Epidemiyolojik Özellikleri ve Korunma: Derleme
Kaya, G., & Altındiş, M. (2022) · Kocaeli Üniversitesi Sağlık Bilimleri Dergisi · doi:10.30934/kusbed.1060956
Gilbert, P. B., & Ph., D. (2002) · Current Problems in Surgery · doi:10.1016/s0011-3840(02)70015-4
Self-citationMolecular signature of COVID-19 prior to its exacerbation by multi-omics surveyPreprint
Suzuki, T., Kita, Y., Yanagida, K., Maeda, K., Hashidate‐Yoshida, T., Nakanishi, H., Ohto‐Nakanishi, T., Terada-Hirashima, J., Tsujimoto, Y., Hojo, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.27.696524
Inhaled Angiopoietin‐Like 4 Antisense Oligonucleotide Therapy for Lung Injury and Fibrosis
Fan, H., Tan, Y., Zhang, J., Liu, X., Qu, J., Chua, D., Cheng, H. S., Kim, J. H. S., Liu, Y. X., Qin, C., et al. (2026) · Advanced Science · doi:10.1002/advs.202501909 · Cited by 2
How effective are COVID-19 vaccines? Here’s what the stats mean … and what they don’t
Froda, S., & Larribe, F. (2021) · doi:10.64628/aam.ws6tptmdh
Vaccine efficacy—the biggest challenge today
Lundstrom, K. H. (2026) · Exploration of Immunology · doi:10.37349/ei.2026.1003260
La vaccination contre la COVID-19 : pourquoi allonger l’intervalle entre les doses?
Quach, C., & Deeks, S. L. (2021) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2021-0323.fr
McGee, R. E., Barrett, D. A., Bednarczyk, R. A., Grant-Whitlock, M., Kegler, M. C., & Arriola, K. J. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127587
Bischof, M. L., Irrgang, P., Tenbusch, M., Keppler, O. T., & Wratil, P. R. (2026) · Medical Microbiology and Immunology · doi:10.1007/s00430-026-00878-y
“Both approved mRNA vaccines, i.e. BNT162b2 and mRNA-1273, encode the Spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as their immunogen and were shown to evoke immune responses that significantly increase protection against severe disease [1, 2].”
What are the rates of adverse events in patients who receive mRNA COVID vaccines?
Hess, M. C., Vondrak, E., & Fray, S. (2022) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001713
Exploring security and privacy challenges in intelligent semantic healthcare
Ali, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33512-9.00008-1
Vacunas asignadas y aplicadas por dosis contra COVID-19 en Colombia: un avance significativo
Pinzón, J. E. D. (2023) · Cultura científica · doi:10.38017/1657463x.822
Laopajon, W., Deesomchok, A., Chaiwong, W., Takheaw, N., Pata, S., Duangjit, P., Inchai, J., Pothirat, C., Bumroongkit, C., Theerakittikul, T., et al. (2025) · Infection and Chemotherapy · doi:10.3947/ic.2024.0145
“Several platforms of vaccine were speedily developed and were demonstrated to induce both neutralizing antibodies (NAb) and cellular immune responses against the virus with the hope of preventing SARS-CoV-2 infection and reducing severity and mortality from COVID-19 [2-7].”
Porobić-Jahić, H., Piljić, D., Jahić, R., Mujić, M., Trnačević, A., Petrović, J., Mustafić, S., Jahić, N., & Tihić, N. (2022) · Medicinski Glasnik · doi:10.17392/1500-22
Jamous, Y. F. (2026) · Pandemics · doi:10.3390/pandemics1020008 · Cited by 2
Kolben, Y., Finkelshtein, E., Code Pharma, T. N., Naftali, E., Code Pharma, T. N., Kenig, A., Kessler, A., Cardoso, F., Lisovoder, N., Code Pharma, T. N., et al. (2022) · Discoveries · doi:10.15190/d.2022.17
Issues in Generalizing Results from Clinical Trials
Piantadosi, S. (2022) · Springer eBooks · doi:10.1007/978-3-319-52677-5_236-1
nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination
Shahid, I. (2022) · Dr Sulaiman Al Habib Medical Journal · doi:10.1007/s44229-022-00006-x
Covid-19 and cancer: impact on diagnosis, care and therapy
Nabil, S. A., Abumsimir, B., Laraqui, A., & Ennaji, M. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824152-3.00023-8
THE EFFECT OF VACCINATON ON COVID-19 DEATHS: A RESEARCH ACCORDING TO COUNTRIES' INCOME GROUPS
ŞENOL, O., ÇIRAKLI, Ü., & GÖKKAYA, D. (2023) · Mehmet Akif Ersoy Üniversitesi İktisadi ve İdari Bilimler Fakültesi Dergisi · doi:10.30798/makuiibf.1033552
Lack of Convincing Evidence That the Widely Used COVID-19 Vaccines Will Produce Herd Immunity
Wormser, G. P., Flatley, C. A., Flatley, E. M., White, P. A., & Montecalvo, M. A. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.01.037 · Cited by 1
Wang, D., Wang, H., Wan, W., Zhu, Z., Sho, T., Zheng, Y., Zhang, X., Dou, L., Ding, Q., Yu, L., et al. (2025) · eLife · doi:10.7554/elife.97621.2
Translational Nanomedicine and Delivery Tools for Cardiovascular Disease Therapy and Diagnostics
Miller, M. A., & Williams, R. M. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-22285-5_10
Side effects of COVID-19 vaccination in Pakistani population: A cross sectional studyPreprint
Ain, Q., Khan, M., Afrah, A., et al. (2023) · Qeios · doi:10.32388/nzcn5i
Les vaccins à ARN messager anti-Covid-19
Reynes, J. (2023) · Actualités Pharmaceutiques · doi:10.1016/s0515-3700(23)00475-5
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.